Nitin Jain, MD

Articles

Dr. Jain on the Utility of UCART22 in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia

January 7th 2022

Nitin Jain, MD, discusses the preliminary results from the phase 1 BALLI-01 study, which investigated UCART22, a genetically modified allogeneic T-cell therapy, in patients with relapsed or refractory B-cell acute lymphoblastic leukemia.

Q&A: Early Treatment of CLL

January 5th 2022

Richard R. Furman, MD, and Nitin Jain, MD, share insight on the evolving treatment landscape of CLL, particularly for treatment in early line settings.

Q&A: Modifying and Switching Therapies in CLL

January 5th 2022

Nitin Jain, MD, and Richard R. Furman, MD, discuss the standard treatment criteria for CLL and answer audience questions on the appropriate circumstances to adjust, switch, and discontinue therapy.

Novel Treatments for the Management of CLL

January 5th 2022

Nitin Jain, MD, comments on the use of novel treatment strategies, including CAR T-cell therapy, being evaluated to treat patients with CLL.

Choosing the Appropriate Treatment Strategy in CLL

December 22nd 2021

Nitin Jain, MD, shares factors to consider when selecting the optimal therapy for patients with CLL.

Using Noncovalent BTK Inhibitors for the Management of CLL

December 22nd 2021

Nitin Jain, MD, provides insight on approaching treatment with noncovalent BTK inhibitors for patients with CLL who have acquired resistance to covalent inhibitors.

Resistance Mechanisms to BTKi in CLL

December 15th 2021

Richard R. Furman, MD, reviews resistance mechanisms to BTK inhibitors and how they affect treatment selection for patients with CLL.

Role of Fixed-Dose Regimens in CLL

December 15th 2021

Nitin Jain, MD, leads the discussion on the use of fixed-dose regimens for the treatment of CLL as seen in the phase 2 CAPTIVATE and phase 3 GLOW trials.

ELEVATE-RR and ALPINE Trials in Relapsed CLL

December 8th 2021

Richard R. Furman, MD, leads the discussion on clinical implications from head-to-head trials of BTK inhibitors in the relapsed setting for patients with CLL.

BTK Inhibitors in the Management of CLL

December 8th 2021

Nitin Jain, MD, and Richard R. Furman, MD, review available treatment options for the treatment of CLL and discuss the safety and tolerability of these therapies.

Dr. Jain on the Combination of Venetoclax and Ibrutinib in CLL

January 12th 2018

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the combination of venetoclax (Venclexta) and ibrutinib (Imbruvica) in chronic lymphocytic leukemia (CLL).

Dr. Jain Discusses Treatment of Richter's Transformation in CLL

May 8th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the treatment of patients with chronic lymphocytic leukemia who have developed Richter’s transformation.

Dr. Jain on PD-1 Expression in Nivolumab/Ibrutinib Combination in CLL

February 24th 2017

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses PD-1 expression in patients with chronic lymphocytic leukemia (CLL) who were treated with the combination of nivolumab (Opdivo) and ibrutinib (Imbruvica).

Dr. Jain on the Combination of Idelalisib and Rituximab for Older Patients With CLL

November 26th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses the efficacy and safety of the combination of idelalisib and rituximab for older patients with chronic lymphocytic leukemia.

Dr. Jain on Increased Lymphocytosis Following Treatment With a B-Cell Receptor Inhibitor

November 5th 2014

Nitin Jain, MD, assistant professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center, discusses lymphocytosis following treatment with a B-cell receptor inhibitor.